GlassScriptPhysician profile
Charanpreet Kaur
NPI 1225758717
$567.30
in general payments reported to CMS, 2019-2025
14 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $92.49 · 2024: $158 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $567.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $214.73 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $58.54 | 2023-2025 | Airsupra, Breztri |
| Amgen INC. | $42.00 | 2024-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $39.79 | 2024-2025 | |
| Aytu Biopharma, INC. | $30.39 | 2023-2024 | Karbinal |
| Corcept Therapeutics | $30.36 | 2025 | Korlym |
| Exact Sciences Corporation | $25.64 | 2023 | Cologuard Collection Kit |
| Grifols USA, LLC | $22.62 | 2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $19.40 | 2024 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $18.26 | 2024 | Shingrix |
| Insulet Corporation | $17.16 | 2025 | Omnipod |
| Medtronic, INC. | $16.96 | 2024 | Intellis Adaptivestim |
| Lilly USA, LLC | $16.59 | 2023 | Mounjaro |
| Paratek Pharmaceuticals, INC. | $14.86 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charanpreet Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.